Analysts forecast that pSivida Corp. (NASDAQ:PSDV) will report earnings per share (EPS) of ($0.13) for the current quarter, Zacks reports. Three analysts have issued estimates for pSivida’s earnings, with estimates ranging from ($0.14) to ($0.12). pSivida reported earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.3%. The company is scheduled to issue its next earnings results on Thursday, May 3rd.

On average, analysts expect that pSivida will report full year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.52). For the next financial year, analysts forecast that the company will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.52) to ($0.41). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover pSivida.

How to Become a New Pot Stock Millionaire

pSivida (NASDAQ:PSDV) last issued its quarterly earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. pSivida had a negative return on equity of 205.82% and a negative net margin of 882.37%. The firm had revenue of $0.93 million for the quarter, compared to the consensus estimate of $0.48 million.

Several brokerages have recently weighed in on PSDV. HC Wainwright set a $5.00 price target on pSivida and gave the stock a “buy” rating in a report on Tuesday. B. Riley set a $5.00 price target on pSivida and gave the stock a “buy” rating in a report on Friday, December 15th. Northland Securities reiterated a “buy” rating and issued a $10.00 price target on shares of pSivida in a report on Monday, December 11th. Finally, ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $7.57.

Shares of PSDV stock opened at $1.16 on Wednesday. pSivida has a fifty-two week low of $0.93 and a fifty-two week high of $2.45. The firm has a market capitalization of $55.67, a P/E ratio of -1.97 and a beta of 1.28.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSDV. Essex Investment Management Co. LLC purchased a new position in pSivida during the 4th quarter worth $173,000. Geode Capital Management LLC increased its holdings in pSivida by 75.0% during the 4th quarter. Geode Capital Management LLC now owns 240,631 shares of the company’s stock worth $259,000 after purchasing an additional 103,150 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in pSivida by 4.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,524,000 shares of the company’s stock worth $1,646,000 after purchasing an additional 59,900 shares during the period. Institutional investors own 10.69% of the company’s stock.

WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at

pSivida Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Get a free copy of the Zacks research report on pSivida (PSDV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with's FREE daily email newsletter.